ERIS Lifesciences Ltd. has reported a robust financial performance for the September 2025 quarter, showcasing significant growth across key metrics. The company, operating in the Pharmaceuticals and Biotechnology sector, has demonstrated a strong operational cash flow, reaching an impressive Rs 1,065.01 crore, marking a notable achievement in its financial trajectory. The latest results indicate that ERIS Lifesciences has maintained a consistent score over the past three months, reflecting stability in its performance. The net sales for the quarter reached Rs 792.41 crore, while the operating profit to net sales ratio stood at a remarkable 36.37%. This efficiency is further highlighted by the operating profit to interest ratio, which is the highest recorded at 5.82 times. Additionally, the company reported a profit before tax (PBT) of Rs 169.86 crore, which has grown significantly, alongside a profit after tax (PAT) of Rs 120.19 crore, reflecting a year-on-year growth of 31.2%. With an earnings per share (EPS) of Rs 8.82, ERIS Lifesciences continues to solidify its position in the market, contributing positively to the overall trend of financial results in the current quarter.